18th June 2022 | Pharma Updates
Cipla to pay Rs 25 crore for a 21% stake in Achira Labs
Cipla Ltd announced that it will acquire a 21.05 percent stake in Achira Labs Pvt Ltd, which is involved in the development and commercialization of point-of-care (PoC) medical test kits in India, for Rs 25 crore.
Drug packaging include a QR code to prevent counterfeiting
Union Health Ministry has made quick response (QR) codes mandatory on the packaging of 300 lifesaving drugs, including Allegra, Augmentin, Shelcal, Azythral, Calpol, Dolo, Fabiflu, Meftal Spas, Montair, and Pan D.
Torrent Pharma's strong domestic outlook remains key growth driver
Following a strong performance in the March quarter (Q4), Torrent Pharmaceuticals expects margin expansion and continued outperformance in the Indian and Brazilian markets.
Walgreens entered clinical trial business to increase access
Walgreens has launched a clinical trial business to reshape the patient experience and increase access and retention in sponsor led drug development research.
Bausch Health halted plans for Solta IPO
Bausch Health Companies Inc announced on Thursday that it was postponing plans for its unit Solta Medical’s initial public offering due to challenging market conditions.
Merck to buy Seagen in order to diversify away from its star cancer drug Keytruda
Merck & Co. already has a stake in Seagen, an antibody-drug conjugate specialist. However, it appears that the New Jersey pharma now wants the entire thing. Merck and Seagen have been discussing the possibility for some time, but no agreement is imminent.
EMA approved Sandoz's application for biosimilar adalimumab high concentration formulation
Sandoz announced that European Medicines Agency has accepted the application for high concentration formulation 100 mg/mL of its biosimilar Hyrimoz (adalimumab) for regulatory review.
